Ketoconazole Cream, 2%

Manufacturer
IPG PHARMACEUTICALS, INC.
Effective date
2026-09-18
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
6
Source
daily-update
Hydrated at
2026-09-22 03:08:15

Label at a glance#

ProductKetoconazole
Active ingredientKETOCONAZOLE
Label structure11 sections

Indications and uses

Ketoconazole cream, 2% is indicated for the topical treatment of tinea corporis, tinea cruris and tinea pedis caused by Trichophyton rubrum, T. mentagrophytes and Epidermophyton floccosum; in the treatment of tinea (pityriasis) versicolor caused by Malassezia furfur (Pityrosporum orbiculare); in the treatment of cutaneous candidiasis caused by Candida spp. and in the treatment of seborrheic dermatitis.

Dosage and administration

It is recommended that ketoconazole cream, 2% be applied once daily to cover the affected and immediate surrounding area. Clinical improvement may be seen fairly soon after treatment is begun; however, candidal infections and tinea cruris and corporis should be treated for two weeks in order to reduce the possibility of recurrence. Patients with tinea versicolor usually require two weeks of treatment. Patients wit...

Label contents#

Full prescribing information#

SPL UNCLASSIFIED SECTION

Rx only

SPL UNCLASSIFIED SECTION

Ketoconazole Cream, 2% contains the broad-spectrum synthetic antifungal agent, ketoconazole 2%. Each gram, for topical administration, contains ketoconazole 20 mg and is formulated in an aqueous cream vehicle consisting of propylene glycol, purified water, cetyl alcohol, stearyl alcohol, isopropyl myristate, sorbitan monostearate, polysorbate 60, polysorbate 80, and sodium sulfite, anhydrous:

Ketoconazole is cis-1-acetyl-4-[4-[[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl] piperazine and has the following structural formula:

image descriptionimage description

M. Formula: C26H28CI2N4O4 M.W :531.44

CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

When ketoconazole cream, 2% was applied dermally to intact or abraded skin of beagle dogs for 28 consecutive days at a dose of 80 mg, there were no detectable plasma levels using an assay method having a lower detection limit of 2 ng/mL.

After a single topical application to the chest, back and arms of normal volunteers, systemic absorption of ketoconazole was not detected at the 5 ng/mL level in blood over a 72-hour period.

Two dermal irritancy studies, a human sensitization test, a phototoxicity study and a photoallergy study conducted in 38 male and 62 female volunteers showed no contact sensitization of the delayed hypersensitivity type, no irritation, no phototoxicity and no photoallergenic potential due to ketoconazole cream, 2%.

Microbiology

MICROBIOLOGY SECTION

Ketoconazole is a broad spectrum synthetic antifungal agent which inhibits the in vitrogrowth of the following common dermatophytes and yeasts by altering the permeability of the cell membrane: dermatophytes: Trichophyton rubrum, T. mentagrophytes, T. tonsurans, Microsporum canis, M. audouini, M. gypseumand Epidermophyton floccosum; yeasts: Candida albicans, Malassezia ovale (Pityrosporum ovale)and C. tropicalis;and the organism responsible for tinea versicolor, Malassezia furfur (Pityrosporum orbiculare).Only those organisms listed in the INDICATIONS AND USAGEsection have been proven to be clinically affected. Development of resistance to ketoconazole has not been reported.

Mode of Action

MECHANISM OF ACTION SECTION

In vitrostudies suggest that ketoconazole impairs the synthesis of ergosterol, which is a vital component of fungal cell membranes. It is postulated that the therapeutic effect of ketoconazole in seborrheic dermatitis is due to the reduction of M. ovale, but this has not been proven.

INDICATIONS AND USAGE

INDICATIONS & USAGE SECTION

Ketoconazole cream, 2% is indicated for the topical treatment of tinea corporis, tinea cruris and tinea pedis caused by Trichophyton rubrum, T. mentagrophytesand Epidermophyton floccosum;in the treatment of tinea (pityriasis) versicolor caused by Malassezia furfur (Pityrosporum orbiculare);in the treatment of cutaneous candidiasis caused by Candida spp.and in the treatment of seborrheic dermatitis.

CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

Ketoconazole cream, 2% is contraindicated in persons who have shown hypersensitivity to the active or excipient ingredients of this formulation.

WARNINGS

WARNINGS SECTION

Ketoconazole Cream, 2% is not for ophthalmic use.

Ketoconazole Cream, 2% contains sodium sulfite anhydrous, a sulfite that may cause allergic-type reactions, including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown and probably low. Sulfite sensitivity is seen more frequently in asthmatic than in nonasthmatic people.

PRECAUTIONS

PRECAUTIONS SECTION

General

GENERAL PRECAUTIONS SECTION

If a reaction suggesting sensitivity or chemical irritation should occur, use of the medication should be discontinued. Hepatitis (1:10,000 reported incidence) and, at high doses, lowered testosterone and ACTH induced corticosteroid serum levels have been seen with orally administered ketoconazole; these effects have not been seen with topical ketoconazole.

Carcinogenesis, Mutagenesis, Impairment of Fertility

CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY SECTION

A long-term feeding study in Swiss Albino mice and in Wistar rats showed no evidence of oncogenic activity. The dominant lethal mutation test in male and female mice revealed that single oral doses of ketoconazole as high as 80 mg/kg produced no mutation in any stage of germ cell development. The Ames' salmonellamicrosomal activator assay was also negative.

Pregnancy

PREGNANCY SECTION

Teratogenic effects

TERATOGENIC EFFECTS SECTION

Pregnancy Category C

SPL UNCLASSIFIED SECTION

Ketoconazole has been shown to be teratogenic (syndactylia and oligodactylia) in the rat when given orally in the diet at 80 mg/kg/day, (10 times the maximum recommended human oral dose). However, these effects may be related to maternal toxicity, which was seen at this and higher dose levels.

There are no adequate and well-controlled studies in pregnant women. Ketoconazole should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Nursing Mothers

NURSING MOTHERS SECTION

It is not known whether Ketoconazole cream, 2% administered topically could result in sufficient systemic absorption to produce detectable quantities in breast milk. Nevertheless, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.

Pediatric Use

PEDIATRIC USE SECTION

Safety and effectiveness in children have not been established.

ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

During clinical trials 45 (5.0%) of 905 patients treated with ketoconazole cream, 2% and 5 (2.4%) of 208 patients treated with placebo reported side effects consisting mainly of severe irritation, pruritus and stinging. One of the patients treated with ketoconazole cream developed a painful allergic reaction.

In worldwide postmarketing experience, rare reports of contact dermatitis have been associated with ketoconazole cream or one of its excipients, namely propylene glycol.

DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

Cutaneous candidiasis, tinea corporis, tinea cruris, tinea pedis, and tinea (pityriasis) versicolor

SPL UNCLASSIFIED SECTION

It is recommended that ketoconazole cream, 2% be applied once daily to cover the affected and immediate surrounding area. Clinical improvement may be seen fairly soon after treatment is begun; however, candidal infections and tinea cruris and corporis should be treated for two weeks in order to reduce the possibility of recurrence.

Patients with tinea versicolor usually require two weeks of treatment. Patients with tinea pedis require six weeks of treatment.

Seborrheic dermatitis

SPL UNCLASSIFIED SECTION

Ketoconazole cream, 2% should be applied to the affected area twice daily for four weeks or until clinical clearing.

If a patient shows no clinical improvement after the treatment period, the diagnosis should be redetermined.

HOW SUPPLIED

HOW SUPPLIED SECTION

Ketoconazole Cream, 2% is supplied in a 45 gram tube.
45 gm tube (71085-008-45)

STORAGE
Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature].

Mfg. Lic. No.: GO/DRUGS/361

Manufactured for:
IPG Pharmaceuticals, Inc.
Phoenix, AZ 85040

Rev.: 07/2025
IKC5/00

STORAGE AND HANDLING SECTION

Product label

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

image descriptionimage descriptionimage descriptionimage description

FDA-Initiated Inactive NDC Indexing#

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
71085-008-60GM - Gram71085-00868b3fd33-5acb-4e1e-a6a5-7bd734d2227012017-06-15

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 10 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
71085-00871085-008-45

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 10 matching rows.

Source Document#

Source XML

Older Hydrated Versions#

Version, Effective date, Source table
VersionEffective dateSourceHydrated
12017-02-14legacy-cache2026-08-02 01:19:18

Orange Book application contexts#

All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.

Orange Book application contexts page 1 of 1 · 1 matching rows.

Source provenance: Browse the complete Orange Book source catalog · source snapshot 43.

Orange Book products#

Current product rows page 1 of 1 · 1 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
A075638-001KETOZOLEKETOCONAZOLE2%CREAM / TOPICALAB2002-12-18

Therapeutic equivalence codes#

Current TE-code rows page 1 of 1 · 1 matching rows.

Application-product, TE code table
Application-productTE code
A075638-001AB

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 2 · 43 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-09-14 22:38:342026-08A075638-001KETOZOLE2%CREAM / TOPICALAB2002-12-1884e616aacf4f…
2026-08-18 06:07:402026-07A075638-001KETOZOLE2%CREAM / TOPICALAB2002-12-18caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A075638-001KETOZOLE2%CREAM / TOPICALAB2002-12-18011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A075638-001KETOZOLE2%CREAM / TOPICALAB2002-12-1831067a03dcf5…
2025-08-23 18:47 UTC2025-08A075638-001KETOZOLE2%CREAM / TOPICALAB2002-12-186a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A075638-001KETOZOLE2%CREAM / TOPICALAB2002-12-18fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A075638-001KETOZOLE2%CREAM / TOPICALAB2002-12-18b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A075638-001KETOZOLE2%CREAM / TOPICALAB2002-12-1803ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A075638-001KETOZOLE2%CREAM / TOPICALAB2002-12-182680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A075638-001KETOZOLE2%CREAM / TOPICALAB2002-12-185bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A075638-001KETOZOLE2%CREAM / TOPICALAB2002-12-18d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A075638-001KETOZOLE2%CREAM / TOPICALAB2002-12-18d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A075638-001KETOZOLE2%CREAM / TOPICALAB2002-12-1879d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A075638-001KETOZOLE2%CREAM / TOPICALAB2002-12-18301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A075638-001KETOZOLE2%CREAM / TOPICALAB2002-12-181e350fbaab3a…
2024-05-31 18:47 UTC2024-05A075638-001KETOZOLE2%CREAM / TOPICALAB2002-12-188072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A075638-001KETOZOLE2%CREAM / TOPICALAB2002-12-185c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04A075638-001KETOZOLE2%CREAM / TOPICALAB2002-12-185d02ea3f76ae…
2022-04-04 05:41 UTC2022-04A075638-001KETOZOLE2%CREAM / TOPICALAB2002-12-184b0b4de00fa7…
2019-12-13 00:20 UTC2019-12A075638-001KETOZOLE2%CREAM / TOPICALAB2002-12-1874a2ff9319b5…
2022-03-09 01:35 UTC2022-03A075638-001KETOZOLE2%CREAM / TOPICALAB2002-12-18bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12A075638-001KETOZOLE2%CREAM / TOPICALAB2002-12-18782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05A075638-001KETOZOLE2%CREAM / TOPICALAB2002-12-1887673890dc5c…
2021-03-12 10:30 UTC2021-03A075638-001KETOZOLE2%CREAM / TOPICALAB2002-12-185aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12A075638-001KETOZOLE2%CREAM / TOPICALAB2002-12-188869cabd3fbd…
2020-11-12 02:37 UTC2020-11A075638-001KETOZOLE2%CREAM / TOPICALAB2002-12-18c0c555d07b60…
2019-12-14 00:12 UTC2019-12A075638-001KETOZOLE2%CREAM / TOPICALAB2002-12-183f01610625f2…
2019-09-15 20:21 UTC2019-09A075638-001KETOZOLE2%CREAM / TOPICALAB2002-12-18b00525d2431f…
2019-07-19 19:46 UTC2019-07A075638-001KETOZOLE2%CREAM / TOPICALAB2002-12-18ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03A075638-001KETOZOLE2%CREAM / TOPICALAB2002-12-186a51e52b5d6a…
2024-02-18 07:12 UTC2024-02A075638-001KETOZOLE2%CREAM / TOPICALAB2002-12-181c564ffb4f44…
2023-12-20 04:57 UTC2023-12A075638-001KETOZOLE2%CREAM / TOPICALAB2002-12-18ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11A075638-001KETOZOLE2%CREAM / TOPICALAB2002-12-18a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10A075638-001KETOZOLE2%CREAM / TOPICALAB2002-12-189b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07A075638-001KETOZOLE2%CREAM / TOPICALAB2002-12-18a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06A075638-001KETOZOLE2%CREAM / TOPICALAB2002-12-183f0d92c62455…
2023-05-13 08:27 UTC2023-05A075638-001KETOZOLE2%CREAM / TOPICALAB2002-12-18053a50430f4f…
2023-01-26 05:58 UTC2023-01A075638-001KETOZOLE2%CREAM / TOPICALAB2002-12-183bdfa0b2c4d7…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11A075638-001KETOZOLE2%CREAM / TOPICALAB2002-12-183a93d1ddd44b…
2022-10-28 04:53 UTC2022-10A075638-001KETOZOLE2%CREAM / TOPICALAB2002-12-18f41ea6bd6efb…

Observed Orange Book normalized TE history#

Normalized TE history page 1 of 2 · 43 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTE codeOrderSource SHA-256
2026-09-14 22:38:342026-08A075638-001AB184e616aacf4f…
2026-08-18 06:07:402026-07A075638-001AB1caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A075638-001AB1011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A075638-001AB131067a03dcf5…
2025-08-23 18:47 UTC2025-08A075638-001AB16a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A075638-001AB1fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A075638-001AB1b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A075638-001AB103ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A075638-001AB12680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A075638-001AB15bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A075638-001AB1d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A075638-001AB1d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A075638-001AB179d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A075638-001AB1301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A075638-001AB11e350fbaab3a…
2024-05-31 18:47 UTC2024-05A075638-001AB18072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A075638-001AB15c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04A075638-001AB15d02ea3f76ae…
2022-04-04 05:41 UTC2022-04A075638-001AB14b0b4de00fa7…
2019-12-13 00:20 UTC2019-12A075638-001AB174a2ff9319b5…
2022-03-09 01:35 UTC2022-03A075638-001AB1bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12A075638-001AB1782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05A075638-001AB187673890dc5c…
2021-03-12 10:30 UTC2021-03A075638-001AB15aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12A075638-001AB18869cabd3fbd…
2020-11-12 02:37 UTC2020-11A075638-001AB1c0c555d07b60…
2019-12-14 00:12 UTC2019-12A075638-001AB13f01610625f2…
2019-09-15 20:21 UTC2019-09A075638-001AB1b00525d2431f…
2019-07-19 19:46 UTC2019-07A075638-001AB1ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03A075638-001AB16a51e52b5d6a…
2024-02-18 07:12 UTC2024-02A075638-001AB11c564ffb4f44…
2023-12-20 04:57 UTC2023-12A075638-001AB1ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11A075638-001AB1a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10A075638-001AB19b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07A075638-001AB1a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06A075638-001AB13f0d92c62455…
2023-05-13 08:27 UTC2023-05A075638-001AB1053a50430f4f…
2023-01-26 05:58 UTC2023-01A075638-001AB13bdfa0b2c4d7…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11A075638-001AB13a93d1ddd44b…
2022-10-28 04:53 UTC2022-10A075638-001AB1f41ea6bd6efb…

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
46b8c283-b88e-6b47-e063-6294a90a3de251363e79-8681-4b68-aebf-09323c95809b2025-12-24Warnings, Adverse reactionsExact identifier
spl set id: 51363e79-8681-4b68-aebf-09323c95809b

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.